Login
Companies $CRON
$3.26 -$0.01 (0.29%) After hours
Cronos Group Inc. logo

Cronos Group Inc.

thecronosgroup.com

What Do They Do?

Sells cannabis flower and other cannabis products to adult-use and medical markets in Canada and internationally.

How Do They Make Money?

Cronos sells cannabis products to customers; most sales happen when products ship or are delivered, while consignment sales happen when customers use the product. Payment terms vary by customer and product.

revenue
SegmentShareRevenue
Cannabis flower
Sold outright

74%
FY2022: 73%
Cannabis extracts
Sold outright

26%
FY2022: 26%
Other
0.3%
FY2022: 0.7%

Who Are Their Customers?

In Canada, adult-use products go to provincial cannabis authorities, with some sales to private retailers; medical products reach users through third-party distributors. International products are sold through pharmacies and third-party distributors.

Do Revenues Turn Into Profits?

Not on paper. It lost $9.4M in FY2025, but brought in more cash than it spent: $149K of free cash flow.

Operating income, FY2025
−12% of revenue
▲ +77% (Loss) vs FY2024 (−$76.5M, −65%)
Net income, FY2025
−6% of revenue
▼ Turned to a loss vs FY2024 ($41.1M, 35%)
Free cash flow, FY2025
0% of revenue
▼ −98% vs FY2024 ($6.4M, 5%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +75%
vs $36.3M in Q3 FY2025
Net income
▼ −47%
vs $26M in Q3 FY2025
Cannabis flower share of revenue vs 72.5% in Q3 FY2025
  • Sep 8, 2026 Cronos extends deadline for CanAdelaar acquisition closing The amended agreement moves the closing deadline to October 15, 2026, while the proposed purchase of all CanAdelaar shares remains in progress.

Growing. Revenue grew 2.3x in 4 years, from $64.6M in FY2021 to $146.6M in FY2025, about 23% a year.

Fermentation manufacturing Exits fermentation-based cannabinoid manufacturing; the older report described a facility for cultured cannabinoids, while the latest says it no longer operates facilities using the Ginkgo collaboration's intellectual property.

Medical brand portfolio Adds LIT as a medical cannabis brand, with products sold in Israel, Germany and the UK; the older report's brand list named Spinach, PEACE NATURALS and Lord Jones.

Revenue over time
Cannabis flower Cannabis extracts Other
$200M$100M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support